

AMENDMENTS

In the claims:

Claims 1-50 (Cancelled).

51. (Previously Presented) A chimeric anti- $\alpha 5\beta 1$ integrin antibody comprising:
a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 1;
a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 7; and
a constant region, wherein the source of the constant region is a human IgG.
52. (Previously Presented) The antibody of claim 51, wherein the source of the constant region is human IgG4 or IgG2M3.
53. (Previously Presented) A pharmaceutical composition comprising the antibody of claim 51, and a physiologically acceptable carrier.
54. (Cancelled)
55. (Cancelled)
56. (Cancelled)
57. (Cancelled)
58. (Previously Presented) A chimeric anti- $\alpha 5\beta 1$ integrin antibody comprising:
a heavy chain consisting of the amino acid sequence of SEQ ID NO: 25; and
a light chain consisting of the amino acid sequence of SEQ ID NO: 26.
59. (Previously Presented) A pharmaceutical composition comprising the antibody of claim 58, and a physiologically acceptable carrier.
60. (Previously Presented) A chimeric anti- $\alpha 5\beta 1$ integrin antibody comprising:
a heavy chain consisting of the amino acid sequence of SEQ ID NO: 28; and

a light chain consisting of the amino acid sequence of SEQ ID NO: 26.

61. (Previously Presented) A pharmaceutical composition comprising the antibody of claim 60, and a physiologically acceptable carrier.

62. (Previously Presented) A humanized anti- $\alpha 5\beta 1$ integrin antibody comprising:
a heavy chain consisting of the amino acid sequence SEQ ID NO: 31; and
a light chain consisting of the amino acid sequence of SEQ ID NO: 32.

63. (Previously Presented) A pharmaceutical composition comprising the antibody of claim 62, and a physiologically acceptable carrier.

Claims 64-78 (Cancelled).